WallStSmart
VBIO

Valion Bio Inc

NASDAQ: VBIO · HEALTHCARE · BIOTECHNOLOGY

$0.97
-5.32% today

Updated 2026-06-02

Market cap
$1.81M
P/E ratio
P/S ratio
1.52x
EPS (TTM)
$-6.66
Dividend yield
52W range
$1 – $6
Volume
0.2M

Valion Bio Inc (VBIO) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20132014201420152015201620162017201720182019201920202020202120212022202320242025
Operating cash flow$-2.13M$-2.13M$-2.50M$-2.50M$-1.69M$-1.69M$-1.38M$-1.38M$-2.89M$-2.89M$-3.67M$-3.59M$-3.59M$-1.61M$-1.61M$-8.92M$-8.51M$-5.72M$-7.00M
Capital expenditures$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$11000.00$118000.00$0.00$581000.00
Depreciation
Stock-based comp$1.22M$416063.00$348451.00$398000.00$271000.00$229000.00$564000.00
Free cash flow$-2.13M$-2.13M$-2.50M$-2.50M$-1.69M$-1.69M$-1.38M$-1.38M$-2.89M$-2.89M$-3.67M$-3.59M$-3.59M$-1.61M$-1.61M$-8.93M$-8.63M$-5.72M$-7.58M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$1.01M$-1.01M$-294297.00$1.06M$-496476.00$5.33M$-3.59M$-1.51M

Frequently asked questions

How much free cash flow does VBIO generate?

VBIO produced $-7.58M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is VBIO's balance sheet healthy?

VBIO holds $12.64M in cash and equivalents against $6.45M in long-term debt, on $16.80M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.